Opinion: The Fatality Burden

Some gain-of-function influenza research poses a significant public health threat and should be banned.

Written byLynn Klotz and Edward Sylvester
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

FLICKR, CHDXXIn August 2013 letters to the journals Science and Nature, 22 virologists notified the research community of their intent to develop and research strains of the already deadly H7N9 influenza virus so that it would be transmissible via aerosols among mammals. The wild-type H7N9 strain is not aerosol transmissible among humans and shows only limited respiratory aerosol transmission among ferrets, so the aim is to confer what is known as gain of function by making the virus mammalian transmissible, or mtGOF. H7N9 caused more than 130 human infections, including 43 fatalities, from handling poultry in China. Those infections tapered off last summer but may be picking up again as flu season approaches.

Back in May, scientists in China published experiments describing hybrids of the H5N1 avian flu virus and the 2009 pandemic H1N1 virus that can be transmitted through the air among guinea pigs. The H5N1 avian flu virus kills more than 60 percent of humans reported infected from handling poultry, but it is rarely contagious among humans.

The voluntary moratorium on research that made the deadly H5N1 avian influenza virus contagious in ferrets via respiratory aerosols lifted this January, and research has resumed. These mtGOF flu strains may already be highly contagious in humans.

These examples of mtGOF research may signal the beginning of widespread interest in making dangerous pathogens such as flu viruses contagious in humans via respiratory aerosols.

What is the likelihood that one ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies